Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 23, 2023
Period End
December 31, 2022
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-K filed February 23, 2023. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded in 2015 to discover, create, test and deliver medicines for genetic diseases and cancers with clear genetic drivers.

The company reports that it has created 15 INDs and had two products approved by the FDA (TRUSELTIQ and NULIBRY). Its net losses were $484.7 milliona in 2022, $586.5 million in 2021 and $505.5 million in 2020, with an accumulated deficit of $1.9 billion as of December 31, 2022. Revenue was $77.6 million in 2022, driven mainly by $74.7 million of license revenue from the Navire-BMS License Agreement, and the company sold its priority review voucher for gross proceeds of $110.0 million.

The lead program, acoramidis for ATTR-CM, failed its Part A primary endpoint at Month 12 (6MWD p = 0.76), but the Part B 30-month outcomes readout is anticipated in mid-2023. The company also lists low-dose infigratinib for achondroplasia, encaleret for ADH1, BBP-418 for LGMD2I, BBP-631 for CAH and a KRAS inhibitor portfolio among its key programs. A January 2022 restructuring initiative cost $43.8 millionb in 2022, and the company expects further charges of $6.0 million to $9.0 million in 2023.

As of December 31, 2022, total consolidated indebtedness was $1.7 billionc, and cash, cash equivalents and marketable securities totaled $428.3 million. Management states these resources, together with restricted cash and equity securities, will fund operations for at least the next 12 months.

Key Highlights

  1. Net loss of $484.7 million in 2022, down from $586.5 million in 2021; accumulated deficit of $1.9 billion as of December 31, 2022.
  2. Total revenue of $77.6 million in 2022, of which $74.7 million was recognized from the Navire-BMS License Agreement for BBP-398 ($90.0 million upfront received in June 2022).
  3. Sold priority review voucher for $110.0 million gross proceeds in June 2022, recognizing a net gain of $107.9 million.
  4. Total indebtedness of $1.7 billion as of December 31, 2022, including $550.0 million 2027 Notes, $747.5 million 2029 Notes and $445.2 million under the Loan Agreement.
  5. Cash, cash equivalents and marketable securities of $428.3 million at year-end 2022; management expects these plus restricted cash and equity securities to fund operations for at least 12 months.
  6. Acoramidis (ATTR-CM) missed its Part A primary endpoint at Month 12 (6MWD p = 0.76); top-line 30-month Part B results are expected in mid-2023.
  7. January 2022 restructuring initiative generated $43.8 million of charges in 2022, with an estimated $6.0 million to $9.0 million more expected in 2023.

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$77.65M$69.72M+11.4%
Cost of Revenue$3.43M$3.11M+10.3%
Gross Profit$74.21M$66.60M+11.4%
R&D Expenses$399.46M$451.02M−11.4%
SG&A Expenses$143.19M$192.21M−25.5%
Operating Expenses$589.85M$646.35M−8.7%
Operating Income-$512.20M-$576.63M+11.2%
Interest Expense$34.14M$46.78M−27.0%
Net Income-$481.18M-$562.54M+14.5%
EPS (Basic)$-3.26$-3.90+16.4%
EPS (Diluted)$-3.26$-3.90+16.4%
Shares Outstanding (Basic)147.47M144.36M+2.2%
Shares Outstanding (Diluted)147.47M144.36M+2.2%

Frequently Asked Questions

  1. Why did BridgeBio's acoramidis trial matter to investors?

    Acoramidis, a TTR stabilizer for ATTR-CM, did not meet its Part A primary endpoint of change from baseline in six-minute walk distance at Month 12 (p = 0.76), with mean declines of 9 meters for acoramidis and 7 meters for placebo. The independent data monitoring committee recommended continuing to the Month 30 endpoint, and the company continues to believe the drug may show benefit on the 30-month hierarchical composite endpoint, with results expected in mid-2023.

  2. What drove the change in revenue in 2022?

    Total revenue rose to $77.6 million from $69.7 million in 2021. License and services revenue of $76.1 million was mainly driven by $74.7 million recognized from the Navire-BMS License Agreement with Bristol-Myers Squibb, while product sales fell to $1.6 million from $3.8 million as TRUSELTIQ selling responsibilities transitioned to Helsinn.

  3. How is BridgeBio funding its operations and debt obligations?

    The company has funded operations through equity sales, convertible notes, term loans, asset sales and licensing. In 2022 it received $110.0 million from the priority review voucher sale and $90.0 million upfront from BMS, and it had $428.3 million in cash and marketable securities at year-end. Future debt service includes $30.6 million of annual interest on the 2029 and 2027 Notes through 2026, plus $37.1 million of term loan payments due in 2023.

  4. What happened to TRUSELTIQ and the Helsinn collaboration?

    Helsinn notified BridgeBio in August 2022 that it would terminate the Amended QED-Helsinn License and Collaboration Agreement for convenience, citing commercial considerations. A Mutual Termination Agreement was signed effective December 21, 2022. Helsinn will stop supplying TRUSELTIQ by March 31, 2023, and QED will be entitled to royalties until then and no future milestone payments.